IL-8 as a potential biomarker in Guillain-Barre Syndrome.
Journal article

IL-8 as a potential biomarker in Guillain-Barre Syndrome.

  • Breville G Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
  • Lascano AM Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
  • Roux-Lombard P Department of Diagnostic Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Department of Medicine, Division of Immunology and Allergy, Geneva University Hospitals, Geneva, Switzerland.
  • Lalive PH Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland, Department of Diagnostic Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • 2020-02-26
Published in:
  • European cytokine network. - 2019
English This pilot study was designed to compare the levels of interleukin-8 (IL-8), a pro-inflammatory chemokine, in the cerebrospinal fluid (CSF) of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), non-inflammatory polyneuropathy (PNP), and other non-inflammatory neurological diseases (functional syndrome or migraine). The results show elevated CSF IL-8 levels in GBS compared to the other groups (p < 0.05). IL-8 could be considered a potential biomarker to differentiate GBS from CIDP. This distinction could be relevant in terms of therapeutic decisions and functional prognosis.
Language
  • English
Identifiers
Persistent URL
https://sonar.ch/global/documents/46701
Statistics

Document views: 21 File downloads: